Literature DB >> 18467692

Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes.

Jeffrey A Fein1, Sophie Sokolow, Carol A Miller, Harry V Vinters, Fusheng Yang, Gregory M Cole, Karen Hoppens Gylys.   

Abstract

The amyloid cascade hypothesis proposes that amyloid beta (Abeta) pathology precedes and induces tau pathology, but the neuropathological connection between these two lesions has not been demonstrated. We examined the regional distribution and co-localization of Abeta and phosphorylated tau (p-tau) in synaptic terminals of Alzheimer's disease brains. To quantitatively examine large populations of individual synaptic terminals, flow cytometry was used to analyze synaptosomes prepared from cryopreserved Alzheimer's disease tissue. An average 68.4% of synaptic terminals in the Alzheimer's disease cohort (n = 11) were positive for Abeta, and 32.3% were positive for p-tau; Abeta and p-tau fluorescence was lowest in cerebellum. In contrast to synaptic p-tau, which was highest in the entorhinal cortex and hippocampus (P = 0.004), synaptic Abeta fluorescence was significantly lower in the entorhinal cortex and hippocampus relative to neocortical regions (P = 0.0003). Synaptic Abeta and p-tau fluorescence was significantly correlated (r = 0.683, P < 0.004), and dual-labeling experiments demonstrated that 24.1% of Abeta-positive terminals were also positive for p-tau, with the highest fraction of dual labeling (39.3%) in the earliest affected region, the entorhinal cortex. Western blotting experiments show a significant correlation between synaptic Abeta levels measured by flow cytometry and oligomeric Abeta species (P < 0.0001). These results showing overlapping Abeta and tau pathology are consistent with a model in which both synaptic loss and dysfunction are linked to a synaptic amyloid cascade within the synaptic compartment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467692      PMCID: PMC2408427          DOI: 10.2353/ajpath.2008.070829

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

Review 2.  Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration.

Authors:  T J Nelson; D L Alkon
Journal:  Biochem Soc Trans       Date:  2005-11       Impact factor: 5.407

3.  Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.

Authors:  John R Cirrito; Kelvin A Yamada; Mary Beth Finn; Robert S Sloviter; Kelly R Bales; Patrick C May; Darryle D Schoepp; Steven M Paul; Steven Mennerick; David M Holtzman
Journal:  Neuron       Date:  2005-12-22       Impact factor: 17.173

4.  Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.

Authors:  Salvatore Oddo; Antonella Caccamo; Levina Tran; Mary P Lambert; Charles G Glabe; William L Klein; Frank M LaFerla
Journal:  J Biol Chem       Date:  2005-11-10       Impact factor: 5.157

5.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.

Authors:  Fernanda G De Felice; Diana Wu; Mary P Lambert; Sara J Fernandez; Pauline T Velasco; Pascale N Lacor; Eileen H Bigio; Jasna Jerecic; Paul J Acton; Paul J Shughrue; Elizabeth Chen-Dodson; Gene G Kinney; William L Klein
Journal:  Neurobiol Aging       Date:  2007-04-02       Impact factor: 4.673

6.  Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation.

Authors:  Q Zheng-Fischhöfer; J Biernat; E M Mandelkow; S Illenberger; R Godemann; E Mandelkow
Journal:  Eur J Biochem       Date:  1998-03-15

7.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers.

Authors:  Pascale N Lacor; Maria C Buniel; Lei Chang; Sara J Fernandez; Yuesong Gong; Kirsten L Viola; Mary P Lambert; Pauline T Velasco; Eileen H Bigio; Caleb E Finch; Grant A Krafft; William L Klein
Journal:  J Neurosci       Date:  2004-11-10       Impact factor: 6.167

8.  A dynamic relationship between intracellular and extracellular pools of Abeta.

Authors:  Salvatore Oddo; Antonella Caccamo; Ian F Smith; Kim N Green; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

9.  Regulation of NMDA receptor trafficking by amyloid-beta.

Authors:  Eric M Snyder; Yi Nong; Claudia G Almeida; Surojit Paul; Timothy Moran; Eun Young Choi; Angus C Nairn; Michael W Salter; Paul J Lombroso; Gunnar K Gouras; Paul Greengard
Journal:  Nat Neurosci       Date:  2005-07-17       Impact factor: 24.884

Review 10.  Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.

Authors:  Gunnar K Gouras; Claudia G Almeida; Reisuke H Takahashi
Journal:  Neurobiol Aging       Date:  2005-10       Impact factor: 4.673

View more
  79 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

Review 2.  Synaptic mitochondrial pathology in Alzheimer's disease.

Authors:  Heng Du; Lan Guo; Shirley ShiDu Yan
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

3.  Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application.

Authors:  Sabine Ott; Andreas Wolfram Henkel; Maria Kerstin Henkel; Zoran B Redzic; Johannes Kornhuber; Jens Wiltfang
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

4.  Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease.

Authors:  Kazuyuki Takata; Yoshihisa Kitamura; Yukinori Nakata; Yasuji Matsuoka; Hidekazu Tomimoto; Takashi Taniguchi; Shun Shimohama
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

5.  Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology.

Authors:  Kaori Morimoto; Juri Horio; Haruhisa Satoh; Lucia Sue; Thomas Beach; Seizaburo Arita; Ikuo Tooyama; Yoshihiro Konishi
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex.

Authors:  Sophie Sokolow; Sanh H Luu; Karabi Nandy; Carol A Miller; Harry V Vinters; Wayne W Poon; Karen H Gylys
Journal:  Neurobiol Dis       Date:  2011-09-03       Impact factor: 5.996

7.  Effect of AmyTrap, an amyloid-β binding drug, on Aβ induced mitochondrial dysfunction and tau phosphorylation in cultured neuroblastoma cells.

Authors:  Omkar Gandbhir; Pazhani Sundaram
Journal:  Metab Brain Dis       Date:  2020-05-04       Impact factor: 3.584

8.  A partially folded structure of amyloid-beta(1-40) in an aqueous environment.

Authors:  Subramanian Vivekanandan; Jeffrey R Brender; Shirley Y Lee; Ayyalusamy Ramamoorthy
Journal:  Biochem Biophys Res Commun       Date:  2011-06-25       Impact factor: 3.575

9.  Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses.

Authors:  G Aleph Prieto; Brian H Trieu; Cindy T Dang; Tina Bilousova; Karen H Gylys; Nicole C Berchtold; Gary Lynch; Carl W Cotman
Journal:  J Neurosci       Date:  2016-12-16       Impact factor: 6.167

10.  Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide.

Authors:  Rina Yamin; Cheng Zhao; Peter B O'Connor; Ann C McKee; Carmela R Abraham
Journal:  Mol Neurodegener       Date:  2009-07-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.